{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:06:15Z","timestamp":1780380375361,"version":"3.54.1"},"reference-count":220,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atopic dermatitis (AD) and alopecia areata are highly prevalent inflammatory skin\/hair conditions. While previously not fully understood and limited in treatment options, AD is currently undergoing a therapeutic revolution. Our increased understanding of the underlying immunologic and barrier dysregulations and disease heterogeneity across its spectrum is facilitating hypothesis-driven therapeutic development. Early transcriptomic analyses in AD skin and blood have identified disease-specific biomarkers and uncovered immune and barrier abnormalities that may contribute to disease pathogenesis. From these findings, various therapeutic targets were then proposed and investigated in clinical trials, leading to the Food and Drug Administration approval of several biologics and small molecule drugs that are now widely used in the clinical setting. Molecular phenotyping of patient samples before and after treatment has further elucidated the specific immunomodulatory effect of each therapeutic, as well as the relative contributions of various immune pathways to disease pathogenesis. This bench-to-bedside cyclical approach has rapidly broadened our understanding of AD and enabled the rapid expansion of the AD therapeutic pipeline. In this brief review, we detail how molecular and blood profiling studies in AD laid the foundation for a therapeutic revolution, discuss currently approved and potential therapeutics for AD resulting from this bench-to-bedside approach, and highlight how this translational approach is being applied to advancing the therapeutic pipeline of alopecia areata.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf049","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:11:07Z","timestamp":1747325467000},"page":"2165-2179","source":"Crossref","is-referenced-by-count":7,"title":["A translational approach to improve therapeutics in atopic dermatitis and beyond"],"prefix":"10.1093","volume":"214","author":[{"given":"Daniel","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Largen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025093003513271400_vkaf049-B1","doi-asserted-by":"crossref","first-page":"875492","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025093003513271400_vkaf049-B2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/cea.14276","article-title":"Trends in eczema prevalence in children and adolescents: a global asthma network phase I study","volume":"53","author":"Langan","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"2025093003513271400_vkaf049-B3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","article-title":"Adult-onset atopic dermatitis: characteristics and management","volume":"20","author":"Vakharia","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2025093003513271400_vkaf049-B4","first-page":"1191","article-title":"Atopic dermatitis: a review of diagnosis and treatment","volume":"60","author":"Correale","year":"1999","journal-title":"Am Fam Physician"},{"key":"2025093003513271400_vkaf049-B5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part I: clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpedi.159.8.745","article-title":"The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis","volume":"159","author":"Chamlin","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2025093003513271400_vkaf049-B7","doi-asserted-by":"crossref","first-page":"adv00556","DOI":"10.2340\/00015555-3918","article-title":"Impact of atopic dermatitis on work and activity impairment in Taiwan","volume":"101","author":"Chan","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2025093003513271400_vkaf049-B8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2018.08.063","article-title":"Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis","volume":"80","author":"Patel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025093003513271400_vkaf049-B10","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025093003513271400_vkaf049-B11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","article-title":"The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature","volume":"82","author":"Pavel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B13","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","article-title":"Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis","volume":"181","author":"Guttman-Yassky","year":"2008","journal-title":"J Immunol"},{"key":"2025093003513271400_vkaf049-B14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/intimm\/dxf109","article-title":"Preferential expression of Th2-type chemokine and its receptor in atopic dermatitis","volume":"14","author":"Uchida","year":"2002","journal-title":"Int Immunol"},{"key":"2025093003513271400_vkaf049-B15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"2025093003513271400_vkaf049-B16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B18","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"2025093003513271400_vkaf049-B19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2011.10400.x","article-title":"Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes","volume":"165","author":"Gutowska-Owsiak","year":"2011","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2009.11.008","article-title":"An update on the genetics of atopic dermatitis: Scratching the surface in 2009","volume":"125","author":"Barnes","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B21","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025093003513271400_vkaf049-B22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/jid.2008.88","article-title":"\u201cOutside-to-inside\u201d (and now back to \u201coutside\u201d) pathogenic mechanisms in atopic dermatitis","volume":"128","author":"Elias","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B23","doi-asserted-by":"crossref","first-page":"e0210013","DOI":"10.1371\/journal.pone.0210013","article-title":"Measurement of trihydroxy-linoleic acids in stratum corneum by tape-stripping: Possible biomarker of barrier function in atopic dermatitis","volume":"14","author":"Chiba","year":"2019","journal-title":"PLoS One"},{"key":"2025093003513271400_vkaf049-B24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaci.2013.07.027","article-title":"Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression","volume":"133","author":"Otsuka","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"2025093003513271400_vkaf049-B26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025093003513271400_vkaf049-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2022.08.026","article-title":"Phenotypic differences of atopic dermatitis stratified by age","volume":"11","author":"Chatrath","year":"2023","journal-title":"JAAD Int"},{"key":"2025093003513271400_vkaf049-B28","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/s41467-023-41857-8","article-title":"Multifaceted analysis of cross-tissue transcriptomes reveals phenotype\u2013endotype associations in atopic dermatitis","volume":"14","author":"Sekita","year":"2023","journal-title":"Nat Commun"},{"key":"2025093003513271400_vkaf049-B29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B30","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"2025093003513271400_vkaf049-B33","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2020.02.021","article-title":"Cutaneous barrier dysfunction in allergic diseases","volume":"145","author":"Leung","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B34","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/ijms23105318","article-title":"Revisiting the roles of filaggrin in atopic dermatitis","volume":"23","author":"Moosbrugger-Martinz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025093003513271400_vkaf049-B35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","article-title":"The role of filaggrin in atopic dermatitis and allergic disease","volume":"124","author":"Drislane","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025093003513271400_vkaf049-B36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","article-title":"TSLP, IL-33, and IL-25: not just for allergy and helminth infection","volume":"150","author":"Stanbery","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B37","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1084\/jem.20130351","article-title":"A role for IL-25 and IL-33\u2013driven type-2 innate lymphoid cells in atopic dermatitis","volume":"210","author":"Salimi","year":"2013","journal-title":"J Exp Med"},{"key":"2025093003513271400_vkaf049-B38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver X receptors in lipid signalling and membrane homeostasis","volume":"14","author":"Wang","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2025093003513271400_vkaf049-B39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chemphyslip.2017.02.006","article-title":"Role of the liver X receptors in skin physiology: Putative pharmacological targets in human diseases","volume":"207","author":"Ouedraogo","year":"2017","journal-title":"Chem Phys Lipids"},{"key":"2025093003513271400_vkaf049-B40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.anai.2018.03.013","article-title":"Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: a randomized controlled trial","volume":"120","author":"Czarnowicki","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025093003513271400_vkaf049-B41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"key":"2025093003513271400_vkaf049-B42","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.3390\/ijms221910381","article-title":"From emollients to biologicals: targeting atopic dermatitis","volume":"22","author":"Salvati","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025093003513271400_vkaf049-B43","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archderm.1986.01660210057018","article-title":"Systemic absorption of topical steroids: metabolic effects as an index of mild hypercortisolism","volume":"122","author":"Garden","year":"1986","journal-title":"Arch Dermatol"},{"key":"2025093003513271400_vkaf049-B44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jdin.2023.05.012","article-title":"Risk of skin atrophy induced by short-term topical corticosteroid use in atopic dermatitis lesional skin: a systematic review","volume":"12","author":"Ricardo","year":"2023","journal-title":"JAAD Int"},{"key":"2025093003513271400_vkaf049-B45","doi-asserted-by":"crossref","first-page":"119s","DOI":"10.1002\/j.1875-9114.1991.tb02641.x","article-title":"Complications associated with immunosuppressive therapy and their management","volume":"11","author":"Min","year":"1991","journal-title":"Pharmacotherapy"},{"key":"2025093003513271400_vkaf049-B46","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B47","first-page":"171","article-title":"IL-13 gene expression in patients with atopic dermatitis: relation to IgE level and to disease severity","volume":"11","author":"Metwally","year":"2004","journal-title":"Egypt J Immunol"},{"key":"2025093003513271400_vkaf049-B48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S260370","article-title":"Targeting IL-4 for the treatment of atopic dermatitis","volume":"9","author":"Chiricozzi","year":"2020","journal-title":"Immunotargets Ther"},{"key":"2025093003513271400_vkaf049-B49","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.97.7.3406","article-title":"Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during T cell receptor stimulation","volume":"97","author":"Huang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025093003513271400_vkaf049-B50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4899-0987-9_21","article-title":"The IL-4 receptor\u2014signaling mechanisms","volume":"365","author":"Keegan","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"2025093003513271400_vkaf049-B51","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B52","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025093003513271400_vkaf049-B53","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B54","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s12325-022-02399-5","article-title":"Dupilumab-treated patients with asthma in the real world: the RAPID global registry","volume":"40","author":"Gall","year":"2023","journal-title":"Adv Ther"},{"key":"2025093003513271400_vkaf049-B56","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B57","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B59","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1097\/DER.0000000000000764","article-title":"Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab","volume":"32","author":"Mikhaylov","year":"2021","journal-title":"Dermatitis"},{"key":"2025093003513271400_vkaf049-B60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B61","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B62","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025093003513271400_vkaf049-B64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B65","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025093003513271400_vkaf049-B66","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B68","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025093003513271400_vkaf049-B69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B70","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J Mol Biol"},{"key":"2025093003513271400_vkaf049-B71","year":"2024"},{"key":"2025093003513271400_vkaf049-B72","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"2025093003513271400_vkaf049-B73","doi-asserted-by":"crossref","first-page":"639097","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025093003513271400_vkaf049-B74","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B75","year":"2024"},{"key":"2025093003513271400_vkaf049-B76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B78","year":"2022"},{"key":"2025093003513271400_vkaf049-B79","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1357-4310(97)01181-7","article-title":"Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease","volume":"4","author":"Weinberg","year":"1998","journal-title":"Mol Med Today"},{"key":"2025093003513271400_vkaf049-B80","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B81","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0161-5890(87)90122-2","article-title":"Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts","volume":"24","author":"Paterson","year":"1987","journal-title":"Mol Immunol"},{"key":"2025093003513271400_vkaf049-B82","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2222.2009.03241.x","article-title":"Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses","volume":"39","author":"Wang","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"2025093003513271400_vkaf049-B83","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","article-title":"Eosinophils and atopic dermatitis","volume":"59","author":"Simon","year":"2004","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bjd\/ljae230","article-title":"The role of OX40L\/OX40 axis signalling in atopic dermatitis","volume":"191","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B86","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40257-024-00850-7","article-title":"OX40 in the pathogenesis of atopic dermatitis-a new therapeutic target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2025093003513271400_vkaf049-B87","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.immuni.2006.03.019","article-title":"Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells","volume":"24","author":"Wang","year":"2006","journal-title":"Immunity"},{"key":"2025093003513271400_vkaf049-B88","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","article-title":"OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab","volume":"14","author":"L\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025093003513271400_vkaf049-B89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B90","year":"2024"},{"key":"2025093003513271400_vkaf049-B91","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.jacig.2023.100195","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2024","journal-title":"J Allergy Clin Immunol Global"},{"key":"2025093003513271400_vkaf049-B92","year":"2024"},{"key":"2025093003513271400_vkaf049-B93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B94","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/bjd\/ljad498.028","article-title":"523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)","volume":"190","author":"Weidinger","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B95","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Gutowska-Owsiak","year":"2012","journal-title":"Exp Dermatol"},{"key":"2025093003513271400_vkaf049-B96","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B97","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B98","doi-asserted-by":"crossref","first-page":"AB239","DOI":"10.1016\/j.jaad.2024.07.951","article-title":"53111 Individual patient responses to IL-22RA1 inhibition in a Phase 2a monotherapy trial for moderate-to-severe atopic dermatitis","volume":"91","author":"Gooderham","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B99","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00403-024-03319-z","article-title":"Interleukin-1\u03b1 inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies","volume":"316","author":"Simpson","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2025093003513271400_vkaf049-B100","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/all.14050","article-title":"Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis","volume":"75","author":"Kang","year":"2020","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B101","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jdv.18727","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025093003513271400_vkaf049-B102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025093003513271400_vkaf049-B103","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"2025093003513271400_vkaf049-B104","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.3390\/jcm11237244","article-title":"Phase 1 and 2 randomized clinical studies determine lack of efficacy for Anti-IL-17C antibody mor106 in moderate\u2013severe atopic dermatitis","volume":"11","author":"Tha\u00e7i","year":"2022","journal-title":"J Clin Med"},{"key":"2025093003513271400_vkaf049-B105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s13555-022-00876-x","article-title":"Risankizumab in patients with moderate-to-severe atopic dermatitis: a phase 2, randomized, double-blind, placebo-controlled study","volume":"13","author":"Tyring","year":"2023","journal-title":"Dermatology and Therapy"},{"key":"2025093003513271400_vkaf049-B106","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B107","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.det.2013.04.008","article-title":"Role of interleukin 1 in atopic dermatitis","volume":"31","author":"Abramovits","year":"2013","journal-title":"Dermatol Clin"},{"key":"2025093003513271400_vkaf049-B108","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages","volume":"113","author":"Netea","year":"2009","journal-title":"Blood"},{"key":"2025093003513271400_vkaf049-B109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.21300","article-title":"Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1","volume":"214","author":"Yano","year":"2008","journal-title":"J Cell Physiol"},{"key":"2025093003513271400_vkaf049-B110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2353\/ajpath.2007.061067","article-title":"The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis","volume":"171","author":"Mee","year":"2007","journal-title":"Am J Pathol"},{"key":"2025093003513271400_vkaf049-B111","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B112","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/jid.2011.446","article-title":"IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors","volume":"132","author":"Savinko","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B113","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2332\/allergolint.13-OA-0672","article-title":"IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand","volume":"63","author":"Murakami-Satsutani","year":"2014","journal-title":"Allergol Int"},{"key":"2025093003513271400_vkaf049-B114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-8-22","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J Inflamm (Lond)"},{"key":"2025093003513271400_vkaf049-B115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjd.21631","article-title":"Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis","volume":"187","author":"Laquer","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025093003513271400_vkaf049-B117","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jaci.2022.10.009","article-title":"IL-33 antagonism does not improve chronic atopic dermatitis: What can we learn?","volume":"150","author":"Schuler","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B118","author":"Loumeau","year":"2019"},{"key":"2025093003513271400_vkaf049-B119","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","article-title":"Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining","volume":"145","author":"Kiehl","year":"2001","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B121","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00557966","article-title":"[Eosinophilic leucocytes in the skin lesions of psoriasis and atopic dermatitis (author\u2019s transl). ]","volume":"254","author":"Steigleder","year":"1975","journal-title":"Arch Dermatol Res (1975)"},{"key":"2025093003513271400_vkaf049-B122","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1365-2222.2003.01803.x","article-title":"Immunological differences between intrinsic and extrinsic types of atopic dermatitis","volume":"33","author":"Akdis","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"2025093003513271400_vkaf049-B123","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0091-6749(94)90347-6","article-title":"Eosinophils in atopic dermatitis","volume":"94","author":"Leiferman","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B124","doi-asserted-by":"crossref","first-page":"155897","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"key":"2025093003513271400_vkaf049-B125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B126","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B127","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J Immunol"},{"key":"2025093003513271400_vkaf049-B128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2020.00341","article-title":"IL-17C\/IL-17RE: emergence of a unique axis in T(H)17 biology","volume":"11","author":"Nies","year":"2020","journal-title":"Front Immunol"},{"key":"2025093003513271400_vkaf049-B129","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jid.2018.02.037","article-title":"IL-17C: a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis","volume":"138","author":"Guttman-Yassky","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"key":"2025093003513271400_vkaf049-B130","year":"2019"},{"key":"2025093003513271400_vkaf049-B131","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B132","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B133","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3389\/fimmu.2020.01557","article-title":"Modulation of signaling mediated by TSLP and IL-7 in inflammation, autoimmune diseases, and cancer","volume":"11","author":"Markovi\u0107","year":"2020","journal-title":"Front Immunol"},{"key":"2025093003513271400_vkaf049-B134","year":"2024"},{"key":"2025093003513271400_vkaf049-B135","doi-asserted-by":"crossref","first-page":"ljae266.090","DOI":"10.1093\/bjd\/ljae266.090","article-title":"717 - Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects","volume":"191","author":"Parish","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp Dermatol"},{"key":"2025093003513271400_vkaf049-B137","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","article-title":"Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis","volume":"107","author":"Hanifin","year":"1996","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B138","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/1523-1747.ep12472344","article-title":"Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition","volume":"100","author":"Chan","year":"1993","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B139","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B140","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2025093003513271400_vkaf049-B141","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0952-7915(93)90112-6","article-title":"Role of IgE in atopic dermatitis","volume":"5","author":"Leung","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"2025093003513271400_vkaf049-B142","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.0905-6157.2003.00106.x","article-title":"Does the severity of atopic dermatitis correlate with serum IgE levels?","volume":"15","author":"Laske","year":"2004","journal-title":"Pediatr Allergy Immunol"},{"key":"2025093003513271400_vkaf049-B143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/jpm12020165","article-title":"Omalizumab: an optimal choice for patients with severe allergic asthma","volume":"12","author":"Kotoulas","year":"2022","journal-title":"J Pers Med"},{"key":"2025093003513271400_vkaf049-B144","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"2025093003513271400_vkaf049-B145","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B146","year":"2014"},{"key":"2025093003513271400_vkaf049-B147","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025093003513271400_vkaf049-B148","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.jid.2023.01.040","article-title":"IgE depletion with ligelizumab does not significantly improve clinical symptoms in patients with moderate-to-severe atopic dermatitis","volume":"143","author":"Bangert","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B149","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2025093003513271400_vkaf049-B150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025093003513271400_vkaf049-B151","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fimmu.2018.00254","article-title":"Targeting IgE antibodies by immunoadsorption in atopic dermatitis","volume":"9","author":"Kasperkiewicz","year":"2018","journal-title":"Front Immunol"},{"key":"2025093003513271400_vkaf049-B152","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B153","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.anai.2023.01.020","article-title":"Oral Janus kinase inhibitors for atopic dermatitis","volume":"130","author":"Mikhaylov","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025093003513271400_vkaf049-B154","doi-asserted-by":"crossref","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"2025093003513271400_vkaf049-B155","year":"2022"},{"key":"2025093003513271400_vkaf049-B156","year":"2023"},{"key":"2025093003513271400_vkaf049-B157","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/healthcare9111575","article-title":"Baricitinib: the first Jak inhibitor approved in europe for the treatment of moderate to severe atopic dermatitis in adult patients","volume":"9","author":"Radi","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"2025093003513271400_vkaf049-B158","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B159","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B160","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B161","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40257-023-00809-0","article-title":"Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids","volume":"24","author":"Silverberg","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025093003513271400_vkaf049-B162","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B163","doi-asserted-by":"crossref","first-page":"e16704","DOI":"10.1016\/j.heliyon.2023.e16704","article-title":"Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"key":"2025093003513271400_vkaf049-B164","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025093003513271400_vkaf049-B165","doi-asserted-by":"crossref","first-page":"adv00764","DOI":"10.2340\/actadv.v102.2075","article-title":"Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"102","author":"Sedeh","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025093003513271400_vkaf049-B166","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innovations"},{"key":"2025093003513271400_vkaf049-B167","doi-asserted-by":"crossref","first-page":"1759720x20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025093003513271400_vkaf049-B168","year":"2022"},{"key":"2025093003513271400_vkaf049-B169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2024.03.002","article-title":"Bruton\u2019s tyrosine kinase inhibition for the treatment of allergic disorders","volume":"133","author":"Lin","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025093003513271400_vkaf049-B170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol"},{"key":"2025093003513271400_vkaf049-B171","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/156802609789044407","article-title":"IRAK-4 inhibitors for inflammation","volume":"9","author":"Wang","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"2025093003513271400_vkaf049-B172","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat Med"},{"key":"2025093003513271400_vkaf049-B173","year":"2023"},{"key":"2025093003513271400_vkaf049-B174","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaci.2016.07.029","article-title":"Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year","volume":"139","author":"Kennedy","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4R\u03b1 blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2025093003513271400_vkaf049-B176","first-page":"1365","article-title":"Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment","volume":"13","author":"Seite","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025093003513271400_vkaf049-B177","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/infdis\/jiy259","article-title":"Application of an agr-specific antivirulence compound as therapy for staphylococcus aureus-induced inflammatory skin disease","volume":"218","author":"Baldry","year":"2018","journal-title":"J Infect Dis"},{"key":"2025093003513271400_vkaf049-B178","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2010.09743.x","article-title":"Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review","volume":"163","author":"Bath-Hextall","year":"2010","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B179","doi-asserted-by":"crossref","first-page":"e790","DOI":"10.1002\/ctm2.790","article-title":"Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial","volume":"12","author":"Weiss","year":"2022","journal-title":"Clin Transl Med"},{"key":"2025093003513271400_vkaf049-B180","article-title":"Interventions to reduce Staphylococcus aureus in the management of eczema","volume":"2019","author":"George","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025093003513271400_vkaf049-B181","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2133.2008.08836.x","article-title":"Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study","volume":"159","author":"Gueniche","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025093003513271400_vkaf049-B182","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00284-021-02395-y","article-title":"Isolation and characterization of a novel phage SaGU1 that infects Staphylococcus aureus clinical isolates from patients with atopic dermatitis","volume":"78","author":"Shimamori","year":"2021","journal-title":"Curr Microbiol"},{"key":"2025093003513271400_vkaf049-B183","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1099\/jmm.0.061028-0","article-title":"Lysins: the arrival of pathogen-directed anti-infectives","volume":"62","author":"Pastagia","year":"2013","journal-title":"J Med Microbiol"},{"key":"2025093003513271400_vkaf049-B184","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2222.2001.01191.x","article-title":"Novel dinucleotide repeat polymorphism in the first exon of the STAT-6 gene is associated with allergic diseases","volume":"31","author":"Tamura","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"2025093003513271400_vkaf049-B185","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2011.06.003","article-title":"The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections","volume":"128","author":"Howell","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B186","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/j.jaci.2006.12.484","article-title":"The role of Stat6 in the murine model of atopic dermatitis","volume":"119","author":"Alenius","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B187","doi-asserted-by":"crossref","first-page":"112663","DOI":"10.1016\/j.intimp.2024.112663","article-title":"Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments","volume":"139","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025093003513271400_vkaf049-B188","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1399-3038.2005.00274.x","article-title":"CTLA-4 expression in T cells of patients with atopic dermatitis","volume":"16","author":"Choi","year":"2005","journal-title":"Pediatr Allergy Immunol"},{"key":"2025093003513271400_vkaf049-B189","doi-asserted-by":"crossref","first-page":"11898","DOI":"10.3390\/ijms222111898","article-title":"New insights into the role of PD-1 and its ligands in allergic disease","volume":"22","author":"Galv\u00e1n Morales","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025093003513271400_vkaf049-B190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025093003513271400_vkaf049-B191","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","article-title":"Defining severity in alopecia areata: current perspectives and a multidimensional framework","volume":"12","author":"King","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025093003513271400_vkaf049-B192","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity","volume":"37","author":"Muntyanu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025093003513271400_vkaf049-B193","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","article-title":"Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis","volume":"88","author":"Okhovat","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B194","year":"2023"},{"key":"2025093003513271400_vkaf049-B195","year":"2022"},{"key":"2025093003513271400_vkaf049-B196","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"2025093003513271400_vkaf049-B197","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jisp.2020.04.007","article-title":"Alopecia areata: a complex cytokine driven disease","volume":"20","author":"Song","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025093003513271400_vkaf049-B198","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications","volume":"10","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"Cells"},{"key":"2025093003513271400_vkaf049-B199","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B200","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1111\/all.14814","article-title":"An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata","volume":"76","author":"Glickman","year":"2021","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B201","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","article-title":"Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation","volume":"84","author":"Glickman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B202","doi-asserted-by":"crossref","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"2025093003513271400_vkaf049-B203","doi-asserted-by":"crossref","first-page":"e2320351","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025093003513271400_vkaf049-B204","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2025093003513271400_vkaf049-B205","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2025093003513271400_vkaf049-B206","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B208","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia areata: current treatments and new directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025093003513271400_vkaf049-B209","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025093003513271400_vkaf049-B210","doi-asserted-by":"crossref","first-page":"2050313X221138452","DOI":"10.1177\/2050313X221138452","article-title":"Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report","volume":"10","author":"Bourkas","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"2025093003513271400_vkaf049-B211","doi-asserted-by":"crossref","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025093003513271400_vkaf049-B212","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2023.10.031","article-title":"Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database","volume":"90","author":"Diaz","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025093003513271400_vkaf049-B213","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"2025093003513271400_vkaf049-B214","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jaip.2020.01.052","article-title":"Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients","volume":"8","author":"Kridin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025093003513271400_vkaf049-B215","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.36849\/JDD.6553","article-title":"The role of antihistamines and dupilumab in the management of alopecia areata: a systematic review","volume":"21","author":"Pham","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"2025093003513271400_vkaf049-B216","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025093003513271400_vkaf049-B217","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B218","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00403-024-03225-4","article-title":"Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study","volume":"316","author":"David","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2025093003513271400_vkaf049-B219","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/all.15561","article-title":"Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata","volume":"78","author":"Renert-Yuval","year":"2023","journal-title":"Allergy"},{"key":"2025093003513271400_vkaf049-B220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and intrinsic types of atopic dermatitis","volume":"58","author":"Tokura","year":"2010","journal-title":"J Dermatol Sci"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/9\/2165\/63198863\/vkaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/9\/2165\/63198863\/vkaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:52:03Z","timestamp":1759218723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/9\/2165\/8133210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":220,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf049","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,15]]}}}